no. | Name |
---|---|
 | A. Baseline evaluation |
1 | CD4 cell count measurement |
2 | Appropriate viral load test timing |
4 | Complete blood count |
6 | Proportion of patients with CD4 count greater than 200 cells/ul |
 | B. Screening |
20 | Cervical cancer screening (basis and follow up) |
21 | Hepatitis C screening (basis and follow up) |
22 | Hepatitis B testing ever (basis and follow up) |
23 | Tuberculosis screening |
24 | Gonorrhea/chlamydia screening (at least once) |
25 | Syphilis screening (annually) |
27 | High-risk sexual behavior screening (annually) |
28 | Papanicolau test in last year (for women only) |
 | C. Immunization |
31 | Hepatitis B vaccination first dose received (if appropriate) |
34 | PCP (pneumocystis jiroveci pneumonia) prophylaxis |
 | E. HIV Monitoring |
38 | Non-detectable HIV viral load at 48 treatment weeks |
43 | Proportion of patients with previous ARV regimen change for whom reason for change in regime is documented |
44 | Proportion of patients on ARV with at least 95% (good) reported adherence on last visit |
47 | proportion of patients with continued care |
49 | HIV counseling and test offered |
 | F. Therapy |
54 | Appropriately prescribed ART |
55 | Proportion of patients on cotrimoxazole prophylaxis with at least 95% reported adherence on last visit |
60 | Proportion of HIV-positive clients given treatment for latent TB infection |
62 | Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment |